- Home
- CRNX vs MIST Comparison
CRNX vs MIST Comparison
Compare CRNX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRNX | MIST |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 131.3M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CRNX | MIST |
|---|---|---|
| Price | $84.86 | $1.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $76.75 | $8.00 |
| AVG Volume (30 Days) | ★ 2.2M | 1.6M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $720.10 | $2,915.14 |
| Revenue Next Year | $184.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $31.00 | $1.00 |
| 52 Week High | $84.89 | $3.06 |
Technical Indicators
Market Signals| Indicator | CRNX | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 89.75 | 50.46 |
| Support Level | $83.47 | $1.01 |
| Resistance Level | N/A | $1.42 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | -0.91 | 0.01 |
| Stochastic Oscillator | 94.89 | 50.00 |
Price Performance
Historical ComparisonAbout CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.